Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2012-10-24
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-11-06 (study day 14.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2012-11-06 (study day 14.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-11-06 (study day 14.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE SWELLING — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-11-22 (study day 30.0); relationship: PROBABLE
Data queries
No data queries.